MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
17.96
+0.47
+2.69%
After Hours: 18.15 +0.19 +1.06% 18:53 04/28 EDT
OPEN
17.55
PREV CLOSE
17.49
HIGH
18.19
LOW
17.52
VOLUME
1.82M
TURNOVER
--
52 WEEK HIGH
49.38
52 WEEK LOW
16.98
MARKET CAP
2.26B
P/E (TTM)
-11.2461
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Apellis Pharmaceuticals (APLS) and Eton Pharmaceuticals (ETON)
TipRanks · 12h ago
Market Challenges and Revenue Dynamics Impacting Apellis Pharmaceuticals: A Hold Rating Analysis
TipRanks · 15h ago
Hold Rating on Apellis Pharmaceuticals Amid Competitive Pressure from Astellas’ Izervay
TipRanks · 16h ago
Weekly Report: what happened at APLS last week (0421-0425)?
Weekly Report · 16h ago
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Market Expansion and Growth Prospects
TipRanks · 3d ago
Apellis Pharmaceuticals Price Target Cut to $21.00/Share From $24.00 by RBC Capital
Dow Jones · 04/21 16:46
Apellis Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
Dow Jones · 04/21 16:46
RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $21
Benzinga · 04/21 16:36
More
About APLS
More
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Recently
Symbol
Price
%Change

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.